PMID- 22260710
OWN - NLM
STAT- MEDLINE
DCOM- 20120601
LR  - 20211021
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 7
DP  - 2012 Jan 19
TI  - Interim-treatment quantitative PET parameters predict progression and death among 
      patients with Hodgkin's disease.
PG  - 5
LID - 10.1186/1748-717X-7-5 [doi]
AB  - PURPOSE: We hypothesized that quantitative PET parameters may have predictive 
      value beyond that of traditional clinical factors such as the International 
      Prognostic Score (IPS) among Hodgkin's disease (HD) patients. METHODS: Thirty HD 
      patients treated at presentation or relapse had staging and interim-treatment 
      PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had 
      IPS >/= 2. Interim-treatment scans were performed at a median of 55 days from the 
      staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP 
      (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented 
      semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake 
      value (SUV mean), maximum SUV (SUV max) and integrated SUV (iSUV) were recorded. 
      We analyzed whether IPS, absolute value PET parameters or the calculated ratio of 
      interim- to pre-treatment PET parameters were associated with progression free 
      survival (PFS) or overall survival (OS). RESULTS: Median follow-up of the study 
      group was 50 months. Six of the 30 patients progressed clinically. Absolute value 
      PET parameters from pre-treatment scans were not significant. Absolute value SUV 
      max from interim-treatment scans was associated with OS as determined by 
      univariate analysis (p < 0.01). All four calculated PET parameters 
      (interim/pre-treatment values) were associated with OS: MTV int/pre (p < 0.01), 
      SUV mean int/pre (p < 0.05), SUV max int/pre (p = 0.01), and iSUV int/pre (p < 
      0.01). Absolute value SUV max from interim-treatment scans was associated with 
      PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were 
      associated with PFS: MTV int/pre (p = 0.01), SUV max int/pre (p = 0.02) and iSUV 
      int/pre (p = 0.01). IPS was associated with PFS (p < 0.05) and OS (p < 0.01). 
      CONCLUSIONS: Calculated PET metrics may provide predictive information beyond 
      that of traditional clinical factors and may identify patients at high risk of 
      treatment failure early for treatment intensification.
FAU - Tseng, Diane
AU  - Tseng D
AD  - Department of Radiation Oncology, Stanford University School of Medicine, 875 
      Blake Wilbur Dr., Stanford, CA 94305, USA. dianet@gmail.com
FAU - Rachakonda, Leelanand P
AU  - Rachakonda LP
FAU - Su, Zheng
AU  - Su Z
FAU - Advani, Ranjana
AU  - Advani R
FAU - Horning, Sandra
AU  - Horning S
FAU - Hoppe, Richard T
AU  - Hoppe RT
FAU - Quon, Andrew
AU  - Quon A
FAU - Graves, Edward E
AU  - Graves EE
FAU - Loo, Billy W Jr
AU  - Loo BW Jr
FAU - Tran, Phuoc T
AU  - Tran PT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120119
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Disease Progression
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Hodgkin Disease/*diagnostic imaging/drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Positron-Emission Tomography
MH  - Prognosis
MH  - *Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC3398283
EDAT- 2012/01/21 06:00
MHDA- 2012/06/02 06:00
PMCR- 2012/01/19
CRDT- 2012/01/21 06:00
PHST- 2011/11/24 00:00 [received]
PHST- 2012/01/19 00:00 [accepted]
PHST- 2012/01/21 06:00 [entrez]
PHST- 2012/01/21 06:00 [pubmed]
PHST- 2012/06/02 06:00 [medline]
PHST- 2012/01/19 00:00 [pmc-release]
AID - 1748-717X-7-5 [pii]
AID - 10.1186/1748-717X-7-5 [doi]
PST - epublish
SO  - Radiat Oncol. 2012 Jan 19;7:5. doi: 10.1186/1748-717X-7-5.